Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 ...
This is an ASCO Meeting Abstract from the 2017 ASCO Annual Meeting I. This abstract does not include a full text component.
Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...
Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) ...
Short-term efficacy of furmonertinib in treatment of NSCLC patients with EGFR exon20 insertion. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a ...
CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...
Panelists discuss how EGFR mutation profiling guides targeted first-line NSCLC therapy and shifts care toward precision medicine. Panelists discuss how understanding EGFR mutations has transformed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results